HealthLilly Reports 50% Remission at Week 52 Among Pediatric Omvoh RespondersBy Naomi CalderOct 19, 2026, 2:51 PM UTC
HealthOSE Reports 47% One-Year Survival With Tedopi in Lung Cancer TrialBy Naomi CalderOct 19, 2026, 8:33 AM UTC
HealthZealand Pharma Reports No Dose-Limiting Safety Findings in ZP9830’s Phase 1 MAD StudyBy Naomi CalderOct 19, 2026, 7:02 AM UTC
HealthXellSmart Says It Completed Enrollment in Phase II Parkinson’s TrialBy Naomi CalderOct 18, 2026, 4:46 AM UTC
